Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Update

Vivani Medical, Inc. (NASDAQ:VANI) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 401,264 shares, an increase of 87.4% from the January 15th total of 214,164 shares. Based on an average daily volume of 771,804 shares, the short-interest ratio is currently 0.5 days. Approximately 1.0% of the company’s stock are short sold. Approximately 1.0% of the company’s stock are short sold. Based on an average daily volume of 771,804 shares, the short-interest ratio is currently 0.5 days.

Insider Activity

In other Vivani Medical news, Director Gregg Williams bought 1,737,765 shares of Vivani Medical stock in a transaction dated Thursday, January 15th. The stock was bought at an average cost of $1.14 per share, for a total transaction of $1,981,052.10. Following the purchase, the director owned 26,564,109 shares in the company, valued at $30,283,084.26. This represents a 7.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders purchased 6,564,645 shares of company stock valued at $7,943,155. Corporate insiders own 46.40% of the company’s stock.

Hedge Funds Weigh In On Vivani Medical

A number of large investors have recently bought and sold shares of VANI. Panagora Asset Management Inc. acquired a new position in Vivani Medical in the second quarter valued at approximately $25,000. Citadel Advisors LLC bought a new stake in shares of Vivani Medical in the 3rd quarter worth approximately $26,000. Susquehanna International Group LLP lifted its holdings in shares of Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares during the last quarter. Jane Street Group LLC acquired a new position in Vivani Medical during the 4th quarter valued at approximately $60,000. Finally, Renaissance Technologies LLC grew its stake in Vivani Medical by 118.4% during the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after buying an additional 53,127 shares during the last quarter. Institutional investors own 6.78% of the company’s stock.

Vivani Medical Price Performance

Vivani Medical stock opened at $1.17 on Friday. Vivani Medical has a 12 month low of $0.91 and a 12 month high of $1.92. The company has a fifty day moving average price of $1.34 and a two-hundred day moving average price of $1.38. The company has a market cap of $91.46 million, a PE ratio of -2.60 and a beta of 3.11.

Vivani Medical (NASDAQ:VANI) last issued its earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. Equities research analysts anticipate that Vivani Medical will post -0.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

VANI has been the topic of several recent analyst reports. Wall Street Zen raised shares of Vivani Medical to a “sell” rating in a report on Saturday, November 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. Finally, Zacks Research upgraded shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 12th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Vivani Medical presently has an average rating of “Hold” and an average price target of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.